Oxford vaccinates first volunteer in Bundibugyo Ebola vaccine trial

SUNDAY, JULY 26, 2026 | The Nation Editorial Team สลับเป็นเสียงผู้ชาย Play Loading... The BD-Ebov team will recruit more volunteers and monitor safety and immune responses after the first ChAdOx1 BDBV dose was administered. The University of Oxford has administered the first dose of its ChAdOx1 BDBV vaccine to a volunteer in a first-in-human clinical trial targeting the Bundibugyo ebolavirus. The vaccine candidate was developed using the same ChAdOx1 platform technology as the Oxford/AstraZeneca COVID-19 vaccine. Developed in partnership with the Serum Institute of India, which has already produced 4,000 doses for the trial and has 620,000 in reserve for potential future use. If early results are positive, further clinical studies are planned in Uganda to gather data for emergency use authorization. The University of Oxford has announced that the first volunteer has received the ChAdOx1 BDBV vaccine candidate in a first-in-human clinical trial of a vaccine against Bundibugyo ebolavirus.